III, A]. Screening for hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) is compulsory.
Staging is carried out according to the Ann Arbor system in consideration of the risk factors listed in Table 1 
examinations before treatment
To identify patients at increased risk for acute and/or longterm complications, cardiac and pulmonary function tests are mandatory prior to treatment. Consultation of an ear, nose and throat specialist should be considered, particularly in patients with involvement of the head and neck region. Since chemo-and radiotherapy can potentially cause permanent fertility damage, reproductive counseling should be offered to young patients of both genders prior to treatment.
treatment of cHL limited stage patients
Combined modality treatment consisting of a brief chemotherapy followed by radiotherapy was shown to result in superior tumor control compared with radiotherapy alone [I, A] [2, 3] . Currently, two or three cycles of adriamycin/bleomycin/ vinblastine/dacarbazine (ABVD) ( Table 2) followed by involved-field radiotherapy (IF-RT) are considered standard of care for limited stage HL. Recently, the final analysis of a large multicenter trial in which patients were randomly assigned to either two or four cycles of ABVD followed by either 20 Gy or 30 Gy IF-RT was performed. As a result, patients of all treatment groups had similar freedom from treatment failure (FFTF) and overall survival (OS) rates so that the least toxic approach consisting of two cycles of ABVD followed by 20 [6] . Similar to limited stage HL, the question of whether radiotherapy is dispensable in selected patients cannot be answered yet. Ongoing trials are evaluating whether treatment might be stratified on the basis of FDG-PET, but none of the trials has been finally analyzed.
advanced stage patients
Advanced stage HL is usually treated with chemotherapy alone. Radiotherapy is confined to patients having large residual masses after chemotherapy. Patients up to 60 years old are treated with either six (patients with complete remission after four cycles) or eight (patients with partial remission after four cycles) cycles of ABVD or eight cycles of BEACOPPescalated followed by a localized radiation with 30 Gy to residual lymphoma >1.5 cm [I-II, A] [7, 8] . However, recent analyses indicate that radiotherapy might be omitted in patients with residual lymphoma and a negative FDG-PET after completion of chemotherapy [9] . In comparison with ABVD, treatment with BEACOPPescalated leads to superior FFTF and OS rates but is associated with an increased toxicity requiring granulocyte colony-stimulating factor (G-CSF) support.
Patients older than 60 years should be treated with 6-8 cycles (depending on the remission status after four cycles) of ABVD followed by a localized radiation with 30 Gy to residual lymphoma >1.5 cm. The BEACOPP regimen should not be used in elderly patients since increased toxicity was observed in this age group [I-II, A] [10] . Ongoing trials are aimed at reducing treatment intensity without compromising efficacy. In most trials, interim FDG-PET is used to distinguish between those patients who can potentially be cured with reduced therapy and those who require standard or even more intensive treatment. This approach seems promising since some trials suggest that interim FDG-PET is a good predictor for treatment failure in patients with advanced HL treated with ABVD [11, 12] . However, treatment stratification on the basis of interim FDG-PET cannot be considered standard yet, and further evidence from randomized trials is necessary. 
prognosis
With modern treatment strategies, 80-90% of patients achieve permanent remission and can be considered cured.
follow-up
History, physical examination and laboratory analysis including full blood cell count, ESR and blood chemistry should be performed every 3 months for the first half year, every 6 months until the fourth year and once a year thereafter [V, D] . Additional evaluation of the thyroid function (TSH) after irradiation of the neck at 1, 2 and at least 5 years is recommended [III, A]. Furthermore, testosterone and literature
